Defense Tech and Data Services Lead Q4 Earnings as Leonardo DRS Outperforms
Leonardo DRS, Inc. reported a strong finish to 2025, buoyed by a record backlog and increased demand for maritime power systems. Meanwhile, Avanos Medical and Clarivate Plc showed resilient results as they navigate sector-specific restructuring and AI integration challenges.
Beat this week
Last 7 days · Earnings
Impact 5.6/10 (+0.4 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 35 percentage points.
This story sits in Earnings — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Finance briefing
Key takeaways
- Leonardo DRS, Inc.
- reported a strong finish to 2025, buoyed by a record backlog and increased demand for maritime power systems.
- Meanwhile, Avanos Medical and Clarivate Plc showed resilient results as they navigate sector-specific restructuring and AI integration challenges.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Leonardo DRS reported a record year-end backlog of $4.7 billion, up 12% year-over-year.
- 2Avanos Medical completed its portfolio optimization, focusing on high-margin digestive health products.
- 3Clarivate Plc saw a 15% increase in subscription revenue driven by new AI-integrated research platforms.
- 4DRS maritime and land systems segment revenue grew by 14% due to Columbia-class submarine contracts.
- 5Avanos Medical reported a 200 basis point improvement in adjusted gross margins following restructuring.
| Metric | |||
|---|---|---|---|
| Primary Sector | Defense Technology | Medical Devices | Information Services |
| Q4 Revenue Trend | Strong Growth | Stable/Restructuring | Moderate Growth |
| Key Growth Driver | Maritime Power Systems | Digestive Health | Generative AI Tools |
| Market Sentiment | Bullish | Neutral/Improving | Cautiously Optimistic |
Analysis
The Q4 2025 earnings cycle has revealed a widening performance gap between defense-linked industrials and the broader healthcare and data sectors. Leonardo DRS (DRS) emerged as a standout performer in this cluster, capitalizing on the ongoing 're-industrialization' of Western defense capabilities. The company's results underscore a pivotal shift in market sentiment, where investors are increasingly prioritizing companies with clear geopolitical hedges and long-cycle government contracts. Leonardo DRS's success is particularly rooted in its dominant position within maritime power and advanced sensing, two areas that have seen accelerated funding as the U.S. Navy and international allies modernize their fleets.
Leonardo DRS reported a record backlog that now exceeds $4.7 billion, a testament to the company's ability to capture high-priority programs. A significant driver of this growth has been the Columbia-class submarine program, where DRS provides critical electric propulsion technology. This 'sole-source' positioning provides a level of revenue visibility that few mid-tier defense contractors can match. Furthermore, the company's integration of recent tactical computing acquisitions has begun to yield margin expansion, as software-defined capabilities carry higher profitability than traditional hardware manufacturing. Analysts note that DRS is successfully transitioning from a component supplier to a lead systems integrator in several key niches, which could lead to further valuation re-rating in 2026.
Leonardo DRS reported a record backlog that now exceeds $4.7 billion, a testament to the company's ability to capture high-priority programs.
In contrast, Avanos Medical (AVNS) and Clarivate Plc (CLVT) represent the complexities of the current macroeconomic environment outside of the defense sphere. Avanos is currently in the final stages of a multi-year transformation plan aimed at shedding lower-margin respiratory health assets to focus on its core digestive health and pain management portfolios. While the Q4 results showed progress in margin recovery, the company continues to face headwinds from hospital capital expenditure constraints. However, the stabilization of its supply chain and a leaner operating model suggest that Avanos is well-positioned for a 'recovery year' in 2026, provided it can maintain its market share in the competitive enteral feeding segment.
What to Watch
Clarivate Plc’s performance highlights the critical role of generative AI in the information services sector. The company reported a notable uptick in subscription revenue, which management attributed to the successful rollout of AI-enhanced research tools across its intellectual property and life sciences platforms. For Clarivate, the challenge remains the cannibalization of legacy products by these new automated tools. The Q4 call emphasized a 'platform-first' strategy, moving away from fragmented data silos toward a unified intelligence layer. This transition is capital-intensive, but the 15% growth in AI-driven subscriptions suggests that the market is beginning to validate Clarivate's pivot.
Looking ahead, the divergence in these three companies' trajectories offers a microcosm of the broader market. Leonardo DRS is operating in a 'tailwinds-only' environment for the foreseeable future, given the bipartisan support for defense modernization. Avanos and Clarivate, however, must rely on operational excellence and technological innovation to drive alpha. Investors should watch for further M&A activity from Leonardo DRS, as the company seeks to fill gaps in its electronic warfare portfolio, and monitor Avanos's ability to execute on its promised 2026 margin targets.
Cite This Page
"Defense Tech and Data Services Lead Q4 Earnings as Leonardo DRS Outperforms." Finance Intelligence Brief, February 26, 2026. https://getfinancebrief.com/story/leonardo-drs-q4-2025-earnings-analysis
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |